AXIM Biotechnologies Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.2yrs
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

AXIM Biotechnologies CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Catalina Valencia	President & Director	less than a year	US$187.50k	8.03% $ 95.4k
Robert Malasek	CFO & Secretary	8.4yrs	US$90.00k	0.016% $ 190.0
Kurt Phinney	Chief Operating Officer	1.5yrs	Veri yok	Veri yok
Sergei Svarovsky	Chief Scientific Officer & Co-Founder of Sapphire Biotech	no data	Veri yok	6.33% $ 75.2k
Douglas Lake	Chief Clinical Officer of Sapphire Biotech	no data	US$164.43k	Veri yok
Alim Seit-Nebi	CTO & Co-Founder of Sapphire Biotech	no data	US$82.22k	Veri yok
Jeffrey Busby	Senior Vice President of Business Development	3.2yrs	Veri yok	Veri yok
Joseph Tauber	Chief Medical Officer & Chairman of the Medical Advisory Board	3.2yrs	Veri yok	Veri yok
Maria J. Moa	Vice President of Product Development - Sapphire Biotech	no data	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim: AXIM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Catalina Valencia	President & Director	less than a year	US$187.50k	8.03% $ 95.4k
Joseph Tauber	Chief Medical Officer & Chairman of the Medical Advisory Board	3.2yrs	Veri yok	Veri yok
Timothy Scott	Independent Director	7.5yrs	US$20.00k	0.11% $ 1.3k
Kelly Nichols	Member of Medical Advisory Board	3.1yrs	Veri yok	Veri yok
Robert Cunningham	Independent Director	7.5yrs	US$20.00k	0.11% $ 1.3k
Blake Schroeder	Director	2.8yrs	US$20.00k	0% $ 0
Michael Stern	Member of Medical Advisory Board	3yrs	Veri yok	Veri yok
Henry Perry	Member of Medical Advisory Board	3.1yrs	Veri yok	Veri yok
Peter O'Rourke	Director	4.3yrs	US$20.00k	0.080% $ 950.0
Laura Periman	Member of Medical Advisory Board	3.1yrs	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AXIM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

AXIM Biotechnologies Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

AXIM Biotechnologies, Inc. Announces Management Changes

AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer

Recent updates

AXIM Biotechnologies, Inc. Announces Management Changes

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. announced delayed annual 10-K filing

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease

AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Files Patent on Fentanyl Neutralizing Antibody Test, Applies for Drug Enforcement Administration License to Work with Controlled Substance

AXIM Biotechnologies, Inc. Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test and Files Provisional Patent

AXIM Biotechnologies, Inc. announced that it has received $0.1 million in funding

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with A Third Covid-19 Vaccine Dose

AXIM Biotechnologies, Inc Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

AXIM Biotechnologies, Inc Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Develops Novel Tear Sample Collector System, Files Patent Application

AXIM Biotechnologies, Inc. Develops Quantitative Rapid Diagnostic Test for Lacritin, Now Boasts Four Dry Eye Disease Point-Of-Care Biomarker Tests

AXIM Biotechnologies, Inc. announced delayed annual 10-K filing

AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9

Centers for Disease Control and Prevention Publishes Axim Biotechnologies-Sponsored Study on Covid-19 Neutralizing Antibodies

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid Covid-19 Neutralizing Antibody Test in Whole Blood At Point-Of-Care Locations in Canada and the EU

AXIM Biotechnologies, Inc. Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants

AXIM Biotechnologies, Inc. announced delayed annual 10-K filing

AXIM Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test

AXIM Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients

AXIM Biotechnologies Releases Preprint Manuscript Describing the Development of Company’S Rapid Point-Of-Care Test That Measures Covid-19 Neutralizing Antibodies

AXIM Biotechnologies, Inc. Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies

AXIM Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

Axim Biotechnologies Files Patent for Face Mask Designed to Capture SARS-CoV-2 COVID-19

AXIM Biotechnologies Files Emergency Use Authorization with the FDA for First–In-Class Covid-19 Rapid Diagnostic Test for Neutralizing Antibodies

CEO

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş